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Introduction
The discovery that GATA2 mutations underlie Emberger syn-
drome — a condition characterized by primary lymphedema 
and predisposition to myelodysplastic syndrome/acute myeloid 
leukemia (MDS/AML) (1) — revealed key roles for this zinc fin-
ger transcription factor in the lymphatic vasculature (2–4). Our 
initial investigations determined that GATA2 protein levels were 
most prominent in lymphatic vessel valves. This observation, 
coupled with our demonstration that GATA2 regulates genes 
important for lymphatic vessel valve development, prompted us 
to investigate whether GATA2 mutations result in lymphedema 
due to defective valve development and/or function. While sev-
eral earlier studies implicated GATA2 in vascular development 
(5–8), the lack of an obvious vascular phenotype in Gata2–/– mice 
prior to their demise around E10.5 has precluded in depth analy-
ses of Gata2 function in vasculogenesis and angiogenesis. SNPs 
in GATA2 have been associated with coronary artery disease 
(9–11), implying a role for GATA2 in arterial development, while 
ablation of gata2a in zebrafish affects morphogenesis of the 
dorsal aorta (12). Recent studies in which Gata2 was deleted in 
hematopoietic and endothelial cell compartments (13), or was 
disrupted due to mutation of an enhancer element important 
for endothelial Gata2 expression (14), suggested that Gata2 is 
important for vascular integrity and for efficient separation of 
the blood and lymphatic vascular networks (13, 14). The depen-
dence of these phenotypes on endothelial versus hematopoietic 
GATA2 was not, however, dissected in these studies.
The lymphatic vasculature plays crucial roles in the return of 
interstitial fluid to the bloodstream, absorption of dietary lipids, 
and trafficking of immune cells. The formation of valves in collect-
ing lymphatic vessels is a key event during maturation of the lym-
phatic vasculature and is crucial for lymph to be efficiently returned 
to the bloodstream; defects in lymphatic valve formation contrib-
ute to aberrant lymphatic function in lymphedema syndromes 
(15). Recent studies have begun to dissect the genes and cellular 
events important for valve morphogenesis in lymphatic vessels. 
Heterozygous germline mutations in the zinc finger transcription factor GATA2 have recently been shown to underlie a 
range of clinical phenotypes, including Emberger syndrome, a disorder characterized by lymphedema and predisposition to 
myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). Despite well-defined roles in hematopoiesis, the functions 
of GATA2 in the lymphatic vasculature and the mechanisms by which GATA2 mutations result in lymphedema have not been 
characterized. Here, we have provided a molecular explanation for lymphedema predisposition in a subset of patients with 
germline GATA2 mutations. Specifically, we demonstrated that Emberger-associated GATA2 missense mutations result 
in complete loss of GATA2 function, with respect to the capacity to regulate the transcription of genes that are important 
for lymphatic vessel valve development. We identified a putative enhancer element upstream of the key lymphatic 
transcriptional regulator PROX1 that is bound by GATA2, and the transcription factors FOXC2 and NFATC1. Emberger GATA2 
missense mutants had a profoundly reduced capacity to bind this element. Conditional Gata2 deletion in mice revealed that 
GATA2 is required for both development and maintenance of lymphovenous and lymphatic vessel valves. Together, our data 
unveil essential roles for GATA2 in the lymphatic vasculature and explain why a select catalogue of human GATA2 mutations 
results in lymphedema.
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a transcription factor heptad that includes SCL, LYL1, LMO2, 
RUNX1, ERG, and FLI-1 (44). ChIP-Seq studies performed across 
a range of cell types demonstrate that GATA2 has distinct sites of 
chromatin occupancy and transcriptional targets in each cell type in 
which it acts, suggesting tissue-specific transcriptional interactions 
(8, 24, 44–46). The zinc fingers of GATA2 serve at least 2 key roles: 
the C-terminal zinc finger mediates binding to WGATAR motifs 
(47, 48), whereas the N-terminal zinc finger mediates protein-pro-
tein interactions with transcriptional cofactors and stabilizes DNA 
binding (37). Many of the heterozygous GATA2 mutations iden-
tified in patients result in either premature truncation of the pro-
tein or impact the C-terminal zinc finger by introducing missense 
alterations to this critical region of the protein. We (3) and others 
(49) have suggested that a complete loss of function of one GATA2 
allele is the key factor that predisposes to lymphedema onset, given 
the clinical heterogeneity in symptoms observed in patients with 
GATA2 mutations. Most GATA2 missense mutations, including the 
prevalent T354M mutation (more than 50 to date), do not correlate 
with lymphedema. Our hypothesis that complete heterozygous loss 
of GATA2 function underlies lymphedema was complicated by the 
description of 3 Emberger syndrome patients with missense muta-
tions R361L, C373R (2), and R396Q (4). This finding prompted us 
to investigate further the mechanisms by which GATA2 Emberger 
mutations impact on GATA2 function.
Here, we sought to determine the specific role of Gata2 in 
lymphatic vascular development, with a particular emphasis on 
valve development, by selectively inactivating Gata2 in the lym-
phatic vasculature. To investigate the mechanisms by which only 
a select catalogue of GATA2 mutations result in lymphedema, we 
assessed the effects of missense GATA2 Emberger mutations on 
the structure and binding to DNA of the GATA2 C-terminal zinc 
finger. Our work demonstrates that Gata2 plays key roles during 
lymphovenous and lymphatic vessel valve formation and provides 
molecular evidence that Gata2 “null” haploinsufficiency under-
lies the propensity to develop lymphedema, through regulation of 
genes, including Prox1 and Foxc2, that are important for lymphatic 
vessel development and valve development.
Results
GATA2 binds to and transactivates PROX1 regulatory elements. Our 
earlier work determined that siRNA-mediated GATA2 knock-
down in primary embryonic mouse LECs resulted in reduced 
PROX1 levels (3). To investigate whether GATA2 regulation of 
Prox1 is mediated directly, we searched for consensus WGATAR 
binding sites in a 4-kb region of the first intron of Prox1, approxi-
mately 4.5 kb downstream from the transcription start site (Prox1 
+4.5 kb), previously shown to be important for SOX18-mediated 
Prox1 expression (50). Five consensus WGATAR sites conserved 
between mouse and human were present in this region (Supple-
mental Figure 1A; supplemental material available online with 
this article; doi:10.1172/JCI78888DS1), and we showed that 
GATA2 is able to drive reporter gene expression from this element 
(Supplemental Figure 1B). We next compared the transcriptional 
activity of an allelic series of germline GATA2 mutants found in 
Emberger syndrome (R361L, C373R, and R396Q), together with 
those found in patients with hematological malignancies but no 
reported lymphedema (hereafter referred to as hematological 
Initiation of valve development is marked by the appearance of 
clusters of cells, often near vessel branchpoints, that exhibit high 
levels of the transcription factors PROX1, FOXC2, and GATA2 
(16–18). These valve-forming cells reorient themselves with 
respect to the longitudinal axis of the vessel, extend into the vessel 
lumen, and form elongated valve leaflets composed of a bilayer of 
endothelial cells sandwiching an extracellular matrix core com-
posed largely of Fibronectin-EIIIA (FN-EIIIA), laminin-α5, and 
EMILIN1 (19–21). Genes identified to be important for lymphatic 
vessel valve development include the transcription factors FOXC2 
and NFATC1 (15, 20, 22), the transmembrane ligand ephrinB2 
(23), integrin-α9 and its ligands FN-EIIIA (19) and Emilin1 (21), 
gap junction proteins connexin37 (CX37) and connexin43 (CX43) 
(16, 24), NOTCH1 (25), SEMA3A together with receptor compo-
nents NRP1 and PLEXINA1 (26, 27), angiopoietin2 (28, 29), TIE1 
(30), and BMP-9 (31). Though the signals that initiate valve devel-
opment are in large part enigmatic, the location of valves predom-
inantly in regions of disturbed flow suggested that mechanical 
stimuli including shear stress might be important valve-initiating 
stimuli. Indeed, human lymphatic endothelial cells (hLECs) sub-
jected to oscillatory shear stress (OSS) in vitro exhibit elevated lev-
els of FOXC2 and Connexin37 (CX37), activation of NFATC1, and 
a change in their morphology from an elongated to cuboidal shape 
(20), as is observed in lymphatic endothelial cells within valve ter-
ritories in vivo (20). The finding that venous valves share expres-
sion of lymphatic valve markers including PROX1, ephrinB2, and 
integrin-α9 — together with a dependence on ephrinB2 and integ-
rin-α9 signalling for their development — suggests that common 
genetic pathways direct valve development in both lymphatic ves-
sels and veins (32).
Another specialized population of valve endothelial cells com-
prises the lymphovenous valves (LVVs) (33, 34). These valves are 
located at the junction of the jugular and subclavian veins with 
the thoracic and right lymphatic ducts and function, together with 
platelets (35), to partition the lymphatic vasculature from the blood 
vasculature. Endothelial cells of the LVVs express PROX1, FOXC2, 
integrin-α9, and integrin-α5 (33, 36), providing further evidence 
that valve development in distinct vascular compartments relies 
on common pathways. Unlike the valves within lymphatic ves-
sels, however, the LVVs comprise one leaflet derived from venous 
endothelial cells and one derived from lymphatic endothelial cells. 
These valves are exquisitely sensitive to changes in Prox1 dosage 
for their development (33); whereas lymphatic vessel valves form 
in Prox1 heterozygous mice, LVVs do not. Little is known regarding 
the mechanisms by which these specialized valves develop. Some 
of the initiating signals may be distinct from those controlling lym-
phatic vessel valve development, given that the flow patterns and 
shear stress to which these venous cells are exposed are likely dif-
ferent to those encountered by lymphatic vessels.
The Gata family of transcription factors (GATA1–6) each con-
tain 2 zinc fingers and bind a consensus WGATAR motif (in which 
W denotes A or T, and R denotes A or G) (37). Although important 
for neural (38, 39) and urogenital (40) development, GATA2 has 
been most extensively studied in hematopoiesis, where it plays sev-
eral key roles. GATA2 is crucial for hematopoietic stem cell devel-
opment during both embryogenesis and adulthood (41–43), and 
in hematopoietic progenitor cells; it acts combinatorially within 
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(Supplemental Figure 1D). Immunoblotting of nuclear lysates was 
performed to ensure that comparable levels of WT and mutant 
GATA2 protein were present in all conditions tested in this assay 
(Supplemental Figure 2). Together, these data suggest that sus-
ceptibility to lymphedema might be directed by differential 
capacity of GATA2 mutants to bind and regulate the expression of 
genes important for development and function of the lymphatic 
vasculature, rather than hematopoiesis.
To investigate in more detail the sites bound by GATA2 in the 
vicinity of the PROX1 locus, we analyzed data deposited in the 
ENCODE database (http://genome.ucsc.edu./encode). A number 
of studies, including 2 undertaken in human microvascular endo-
thelial cells (HMVECs) (24) and human umbilical vein endothelial 
cells (HUVECs) (8), demonstrated prominent GATA2 binding to 
a region 11 kb upstream of the first, noncoding exon of PROX1. 
Scanning of the DNA sequence in this peak region revealed a 
highly conserved region of approximately 150 nucleotides con-
mutants: germline T354M, 355del, R398W, somatic L359V, and 
R362Q), with the transcriptional activity of WT GATA2 (Sup-
plemental Figure 1B). In all cases, the ability of GATA2 mutants 
to drive reporter gene expression mediated by the Prox1 +4.5 kb 
element was reduced compared with WT. The ability of GATA2 
to bind to each of the 5 consensus sites in the Prox1 +4.5 kb ele-
ment was then assessed using Western blot combined with elec-
trophoretic mobility shift assays (WEMSA) (51). The fourth of 5 
sites, located proximal to the SOX A site, displayed highest levels 
of binding by GATA2 (Supplemental Figure 1C), likely due to the 
presence of 2 overlapping GATA sites in this region. The GATA2 
Emberger mutants and 355del (lacking the majority of the C-ter-
minal zinc finger) almost completely lost the capacity to bind 
this site in Prox1 +4.5 kb (Supplemental Figure 1D). In contrast, 
the germline GATA2 T354M mutation — found in MDS/AML 
but not to date in any patients with lymphedema — and several 
other hematological mutants retained the ability to bind this site 
Figure 1. GATA2 Emberger mutants have reduced capacity to bind and transactivate a novel PROX1 –11 kb enhancer element. (A) Schematic demonstrat-
ing location of PROX1 –11 kb enhancer element relative to the PROX1 gene and arrangement of consensus transcription factor binding sites. (B) Treatment 
of hLECs with GATA2 siRNA results in substantial reduction in PROX1 levels. (C) Mutation of the GATA binding site (BS) in the PROX1 –11 kb element 
reduced luciferase activity mediated by WT GATA2. EV, empty vector control. Error bars correspond to ± SEM, n = 5 independent experiments. *P < 0.05, 
by 2-tailed Student’s t test. (D) The PROX1 –11 kb and +4.5 kb elements cooperatively enhance luciferase activity. Fold-change is shown relative to EV 
controls. Error bars correspond to ± SEM, n = 3 independent experiments. *P < 0.05, by 2-tailed Student’s t test. (E) HEK293 cells were cotransfected with 
GATA2 (WT or mutant) expression constructs together with a PROX1 –11 kb luciferase reporter construct. Luciferase activity was measured after 24 hours. 
Error bars correspond to ± SD (n = 6) from 2 independent experiments (1-way ANOVA, *P < 0.05 relative to WT GATA2) Emberger mutants (here and in 
subsequent panels) are labeled red. (F) Binding of WT and mutant GATA2 proteins to the PROX1 –11 kb element, assessed by WEMSA.
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ment (containing GATA sites 4 and 5, see Methods for details) act-
ing as a promoter. This addition resulted in a significant increase in 
luciferase activity, demonstrating that the Prox1 –11 kb element is 
capable of acting as an enhancer (Figure 1D). We next investigated 
the capacity of the GATA2 mutants to drive reporter gene expres-
sion from the –11 kb enhancer element. All mutants demonstrated 
substantially reduced ability to drive reporter gene expression (Fig-
ure 1E). The relative affinity of WT and mutant GATA2 binding to 
the GATA site in PROX1 –11 kb was then assessed using WEMSA 
(51) (Figure 1F). As observed with the Prox1 +4.5 kb GATA site (Sup-
plemental Figure 1D), the binding of Emberger syndrome mutants 
R361L and C373R to the PROX1 –11 kb GATA site was substantially 
reduced, especially in the case of C373R, where binding was com-
pletely abolished (Figure 1F). In contrast, apart from the 355del 
mutant, the hematological GATA2 mutants retained demonstrable 
binding to the PROX1 –11 kb GATA site.
GATA2 Emberger mutants exhibit reduced DNA-binding affinity. 
The binding of GATA2 mutants to the PROX1 –11 kb GATA site was 
next investigated using EMSA and recombinant purified C-termi-
nal zinc finger constructs (Figure 2A). EMSAs demonstrated that 
the hematological GATA2 mutant R362Q does not significantly 
affect binding to DNA, whereas the hematological GATA2 mutants 
T354M and R398W bound with moderately reduced affinity (Fig-
ure 2A). More strikingly, all 3 Emberger mutants R396Q, C373R, 
and R361L exhibited much lower levels of binding to DNA, with 
gel-shifts evident only at very high concentrations of GATA2 (Fig-
taining a WGATAR motif, together with consensus binding sites 
for key transcriptional regulators of lymphatic vessel valve devel-
opment, FOXC2 and NFATC1 (ref. 22, Figure 1A, and Supplemen-
tal Figure 3). Moreover, hallmarks of an active enhancer element, 
including a DNaseI hypersensitivity site and a histone H3 at lysine 
4 (H3K4Me1) ChIP peak, were evident in this region (see below). 
Treatment of adult human dermal lymphatic microvascular endo-
thelial cells HMVEC-dLyAd (hLEC) with GATA2 siRNA con-
firmed that GATA2 knockdown results in substantially reduced 
PROX1 levels in primary adult hLECs (Figure 1B). Together, 
these data raised the likelihood that the –11 kb region harbors an 
enhancer element important for regulating PROX1 expression and 
suggested that GATA2 binding to this element might be important 
for controlling PROX1 transcription.
To establish whether GATA2 binding is capable of driving 
reporter gene expression from the –11 kb element, an 832 bp frag-
ment encompassing the WGATAR motif was cloned into pGL4.12 
(Promega) and transfected into HEK293 cells together with an 
expression construct containing WT GATA2. Luciferase expression 
was substantially elevated in GATA2 transfected cells compared 
with cells transfected with a vector control (Figure 1C). Mutation 
of the GATA site from GATA to CTTA reduced luciferase expres-
sion by approximately 25% (Figure 1C), demonstrating that GATA2 
binding to this site is important for optimal enhancer activity. The 
–11 kb element was also cloned distally into the enhancer site of 
pGL4.12, together with a subcloned region of the Prox1 +4.5 kb ele-
Figure 2. GATA2 Emberger mutants 
exhibit reduced DNA-binding 
affinity. (A) EMSA analyses using 
recombinant, purified GATA2 WT 
C-terminal zinc finger (CF) and 
mutants showing that Emberger 
mutants (red) exhibit negligible 
binding to the PROX1 –11 kb ele-
ment. (B) Far-UV CD spectra and (C) 
1-D H1 NMR spectra (amide region) 
of recombinant purified proteins 
at 25°C, pH 7.4 in 20 mM sodium 
phosphate, 50 mM NaCl,  
1 mM DTT showing C373R is largely 
disordered and that T354M is partly 
disordered. (D) Structure of the 
C-terminal finger of GATA3 (cyan) 
bound to DNA (gray; Protein Data 
Bank accession code 4hc7 [http://
www.rcsb.org/]) showing positions 
of mutated residues. Emberger 
mutations are shown as red sticks, 
residues that moderately affect 
DNA binding by EMSA are shown 
as magenta sticks, and those that 
show WT binding are shown as 
pink sticks. Other zinc-coordinat-
ing residues are shown as yellow 
sticks, and zinc as a gray sphere.
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minal zinc finger from folding and binding to DNA. The T354M 
mutation appears to be molten globule–like with high levels of sec-
ondary but poorly packed tertiary structure. This smaller disrup-
tion to folding allows the protein to bind DNA, probably through a 
binding and folding mechanism, albeit with reduced affinity. The 
structure of the GATA2 C-terminal zinc finger has not been deter-
mined. However, the zinc finger domains of GATA1–3 are highly 
conserved, with all mutated residues being identical (Supplemen-
tal Figure 5). A homology model of the GATA2 C-terminal zinc fin-
ger (Supplemental Figure 5), based on GATA3 bound to DNA (52) 
indicates that the Emberger R361L and R396Q mutations likely 
disrupt binding to DNA by mutation of key residues that interact 
with the major and minor grooves, respectively (Figure 2D). R362 
makes some minor interactions with phosphates on the backbone 
ure 2A). The purity of GATA2 WT and Emberger zinc fingers was 
assessed by SDS-PAGE analysis prior to use in EMSA assays (Sup-
plemental Figure 4). Folding of these mutants was assessed by far-
UV circular dichroism (CD) spectroscopy and 1D H1-NMR spec-
troscopy (Figure 2, B and C) to assess secondary-structure content 
and overall fold, respectively. The CD data indicates that all 
mutants apart from C373R have WT-like levels of secondary struc-
ture. Both the CD and NMR spectra for C373R are characteristic 
of a largely disordered protein domain with a blue-shifted mini-
mum in the CD spectrum and poor peak dispersion in the NMR 
spectrum. T354M also shows some disruptions to structure in the 
NMR spectrum with peak dispersion intermediate between that 
of the WT and C373R proteins. These data indicate that mutation 
of a zinc-coordinating residue, C373, prevents the GATA2 C-ter-
Figure 3. Occupancy of chromatin at the PROX1 –11 kb enhancer element. (A) PROX1 locus as viewed in UCSC Human Genome Browser (http://genome.
ucsc.edu/). Red boxed area indicates approximate location of the PROX1 –11 kb enhancer element. (B) ChIP demonstrates that GATA2, FOXC2, and NFATC1 
ChIP at the PROX1 –11 kb enhancer in LECs and BECs, but not K562 cells. Where error bars are shown, error bars represent ± SEM, n ≥ 3 independent experi-
ments. Where error bars are not shown, data represents an average of 2 independent experiments. (C) ChIP-seq profile illustrating occupancy of the PROX1 
locus by GATA2 in lymphatic endothelial cells. (D) ChIP with markers of active (H3K4Me1) and inactive/repressed (H3K27Me3) chromatin at the PROX1 –11 
kb element demonstrates that PROX1 –11 kb is active in LECs and repressed in BECs and K562. Data are representative of 2 independent experiments.
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of DNA, but this interaction is fairly solvent exposed, and muta-
tion to polar glutamine likely has very little effect on DNA binding. 
Based on data for GATA3-DNA interactions, R398 should not play 
a direct role in binding to WGATAR sites (52) (but is involved in 
binding to pseudo-palindromic CTACTGATA sites through bind-
ing in the minor groove), so moderate loss of DNA binding likely 
arises from loss of long-range electrostatic interactions between 
the positively charged arginine sidechain and the negatively 
charged DNA. Overall, these data support the hypothesis that sub-
stantial losses in PROX1 –11 kb binding, through mutation of key 
structural or DNA-interacting residues in the C-terminal zinc fin-
ger of GATA2, correlate with lymphedema.
The PROX1 –11 kb locus is differentially regulated in lymphatic 
compared with blood vascular endothelial cells. We next investi-
gated the binding of GATA2 to the PROX1 –11 kb region in both 
adult human dermal lymphatic microvascular endothelial cells 
(hLEC) and adult human dermal blood microvascular endothelial 
cells (hBECs) using ChIP. Hallmarks of an active enhancer ele-
ment, including a DNaseI hypersensitivity site and an H3K4Me1 
ChIP peak, were evident in this region (Figure 3A). Substantial 
occupancy of GATA2 at the –11 kb site was obvious in hLECs, 
using both ChIP (Figure 3B) and ChIP-Seq approaches (Figure 
3C). ChIP experiments also detected GATA2 binding, though to a 
lesser extent, at the PROX1 –11 kb region in hBECs (Figure 3B). In 
contrast, no significant occupancy at this site was detected in ery-
throleukemic K562 cells (Figure 3B), which express GATA2 but not 
PROX1. Given our observation that consensus sites for FOX and 
NFAT transcription factors lie in close proximity to the GATA site 
in PROX1 –11 kb, we next employed ChIP to investigate the occu-
pancy of chromatin by FOXC2 and NFATC1 in hLECs, hBECs, and 
K562 cells. As with GATA2, marked occupancy of the PROX1 –11 
kb region by both FOXC2 and NFATC1 was observed in hLECs, 
and to a lesser extent hBECs, but not in K562 cells (Figure 3B). 
Given that FOXC2 and NFATC1 have been shown to physically 
associate and cooperatively regulate transcription (22), we inves-
tigated potential protein-protein interactions between GATA2, 
NFATC1, and FOXC2 using coimmunoprecipitation. We con-
firmed an interaction between FOXC2 and NFATC1 in HEK293 
cells ectopically expressing these proteins, but no interaction was 
detected between GATA2 and FOXC2, nor between GATA2 and 
NFATC1 (Supplemental Figure 6).
With the exception of the embryonic cardinal veins (53), LVVs 
(33), and venous valves (32), substantial levels of PROX1 are not 
detected in blood vascular endothelial cells. We reasoned that 
reduced binding of GATA2, FOXC2, and NFATC1 at PROX1 –11 
kb in hBECs compared with hLECs was not sufficient to explain 
Figure 4. Localization of GATA2 in 
valves and arteries. (A–E) Immu-
nostaining of E13.5 WT mouse tissue 
sections demonstrated that GATA2 is 
present at higher levels in the endo-
thelial cells comprising LVV leaflets 
(E, arrows) compared with endothelial 
cells lining the jugular veins and jugular 
lymph sacs (E, arrowheads). GATA2 is 
also present in cardiac valves (F–I) and 
arterial endothelial cells (J–M). Boxed 
region in A is shown at a higher magni-
fication in B–E. Scale bars: 50 μm. JLS, 
jugular lymph sac; JV, jugular vein; VA, 
vertebral artery.
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why PROX1 is generally silent in hBECs. To investigate the mech-
anisms by which the PROX1 –11 kb region may contribute to turn-
ing PROX1 “on” in LECs and “off ” in BECs, we investigated the 
status of chromatin in the PROX1 –11 kb region in hLECs, hBECs, 
and K562 cells. ChIP for a marker of active chromatin, H3K4Me1, 
demonstrated substantial levels of this histone mark at PROX1 –11 
kb in hLECs, much lower levels in hBECs, and none in K562 cells 
(Figure 3D), consistent with the transcription factor analysis. Con-
versely, no association of the repressive histone mark histone H3 
on lysine 27 (H3K27Me3) was detected at PROX1 –11 kb in hLECs, 
while this mark was present in hBECs and K562 cells (Figure 3D). 
Together, these data provide further evidence that the PROX1 –11 
kb region harbors an enhancer element important for regulating 
PROX1 expression in the vasculature and suggest that chromatin 
modifications that act to silence this region are important in keep-
ing PROX1 switched off in blood vessels.
GATA2 is present at prominent levels in lymphatic vessel valves, 
LVVs, cardiac valves, and arteries. In addition to lymphedema, 
other cardiovascular phenotypes described in patients harboring 
GATA2 mutations or polymorphisms include venous thromboses, 
culture negative endocarditis (49), and susceptibility to coronary 
artery disease. Given that our early work documented high levels 
of GATA2 in lymphatic vessel valves (3), we analyzed GATA2 lev-
els in LVVs and cardiac valves. Prominent levels of GATA2 were 
observed in the endothelial cells that comprise LVVs (Figure 4, 
A–E). In comparison to the low level of GATA2 protein obvious 
in the endothelial cells lining the jugular vein and the lymph sacs 
(Figure 4E, arrowheads), GATA2 levels in the cells comprising the 
valve leaflets was greatly elevated (Figure 4E, arrows). GATA2 was 
also obvious, together with prominent PROX1 and more restricted 
FOXC2 staining, in semilunar valves of the embryonic heart (Fig-
ure 4, F–I). Taken together, these data suggest that — like PROX1, 
FOXC2, and NFATC1 — GATA2 marks valve endothelial cells 
across distinct vascular compartments. GATA2 protein was also 
obvious in arterial endothelial cells at a discernibly higher level 
than in veins and lymphatic vessels, though at a lower level than 
that present in valve endothelial cells (Figure 4, J–M).
GATA2 levels are elevated in response to oscillatory flow. To 
investigate the mechanisms by which GATA2 is elevated in 
valves, we assessed the effects of exposing hLECs to oscillatory 
flow in vitro. Previous work established that subjection of hLECs 
to OSS, reflective of the turbulent flow pattern characteristic of 
vessel branchpoints, promoted the acquisition of many of the 
cellular characteristics of valve-forming cells (16). These fea-
tures include cytoskeletal remodeling and adoption of a cuboidal 
rather than elongated cell shape, activation of calcineurin/NFAT 
signaling, and elevation of CX37 levels. Moreover, acquisition of 
these characteristics was found to be dependent on PROX1 and 
FOXC2 (16). Our previous work demonstrated that reduction of 
Gata2 levels in primary mouse LECs (mLECs) resulted in greatly 
diminished levels of both Prox1 and Foxc2, suggesting that GATA2 
might lie upstream of these key transcription factors in the hier-
archy of events required for the initiation of valve development 
(3). Taking these data into account, we reasoned that GATA2 may 
be responsive to mechanical stimuli including shear stress and 
hypothesized that elevated GATA2 levels may be required for the 
induction of FOXC2 levels mediated by OSS. Exposure of hLECs 
to OSS for 48 hours resulted in elevated GATA2 mRNA levels 
and significantly higher levels of GATA2 protein in the nuclei 
of hLECs (Figure 5, A, B, and E, and Figure 6, A and C). Accord-
ingly, hLECs adopted a characteristic cuboidal morphology in 
response to OSS, and the levels of nuclear FOXC2 were markedly 
elevated (Figure 5, C, D, and Figure 6, G–I). To assess whether 
the elevation in FOXC2 levels in response to OSS was dependent 
on GATA2, hLECs were treated with control (Figure 6, A–C, and 
G–I) or GATA2 siRNA (Figure 6, D–F, and J–L) and exposed to 
laminar (Figure 6, B, E, H, and K) or oscillatory (Figure 6, C, F, I, 
and L) flow. Strikingly, FOXC2 levels were much lower in GATA2 
siRNA–treated cells exposed to OSS (Figure 6L) compared with 
control siRNA–treated cells (Figure 6I). These data suggest that 
OSS, typical of turbulent flow at vessel branchpoints, may be one 
of the stimuli by which GATA2 levels are elevated in developing 
valves and reveal that elevation of FOXC2 levels in response to 
OSS is dependent on GATA2.
GATA2 is required for lymphatic vascular development. In 
order to assess the requirement for GATA2 for lymphatic vascu-
lar development and, in particular, for valve development, we 
utilized a number of approaches to conditionally delete Gata2 
in the vasculature. The first was to delete Gata2 in vascular and 
hematopoietic compartments by crossing Tie2-Cre mice (54) 
Figure 5. In vitro OSS increases GATA2 levels in hLECs. hLECs were cul-
tured under static conditions (A and C) or subjected to OSS (4 dyn/cm2, 
1/4 Hz) (B and D) for 48 hours. Immunostaining for GATA2 and FOXC2 
demonstrated elevated levels of nuclear GATA2 (A, B, and E) and FOXC2 
(C and D) following exposure of hLECs to OSS. Error bars correspond 
to ± SEM, n = 4 independent experiments. *P < 0.00001, by 2-tailed 
Student’s t test. Scale bars: 50 μm.
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compared with I, L, and M). To investigate the underly-
ing cause of enlarged jugular lymph sacs, we quantified 
proliferating lymphatic endothelial cells in the jugular 
lymph sacs of GataΔEC embryos and their control litter-
mates; the number of Ki67-positive, proliferating lym-
phatic endothelial cells was elevated approximately 
4-fold in E13.5 GataΔEC embryos (Supplemental Figure 
7). To investigate the nature of the blood-filled lym-
phatic phenotype, we analyzed the structure of LVVs, 
which function together with platelet clotting to prevent 
blood from entering the lymphatic vasculature (33, 35). 
At E13.5, the leaflets of the LVVs appeared multilayered 
in GataΔEC embryos compared with their control coun-
terparts (Figure 7, O and P, compared with J and K), 
suggesting that structural abnormalities in LVV devel-
opment might permit the entry of blood to the jugular 
lymph sacs. In addition, the levels of PROX1 observed 
in the venous leaflets of the LVVs (PROX1-positive, 
Podoplanin-negative, Endomucin-low cells) were sub-
stantially lower in GataΔEC embryos compared with 
their control counterparts (Figure 7, P compared with 
K, arrows), suggesting that the identity and function of 
venous valve endothelial cells might be affected. Poten-
tial defects in platelet clotting as a result of Gata2 dele-
tion in both hematopoietic and endothelial compart-
ments in these mice might also contribute to the failure 
of effective separation of the blood and lymphatic vas-
cular networks. Blood-filled jugular lymph sacs and 
dermal lymphatic vessels (Figure 7, Q and R, compared 
with L and M) and focal hemorrhages (Figure 7N) were 
also observed in the skin of GataΔEC embryos compared 
with control (Figure 7I). These data reveal that Gata2 is 
not required for the initiation of Prox1 expression, nor 
for the specification and early migration of lymphatic 
endothelial progenitor cells, but is required for normal 
LVV development and effective separation of the blood 
vasculature from the lymphatic vasculature.
We next investigated the consequences of selective Gata2 
deletion in the lymphatic vasculature by crossing Prox1-CreERT2 
mice (56) with Gata2fl/fl mice and inducing Gata2 deletion at a 
range of embryonic stages (55) (Gata2ΔLEC). To compare the con-
sequences of selectively deleting Gata2 in the lymphatic vascula-
ture to pan-endothelial and hematopoietic deletion, we adminis-
tered tamoxifen at E10.5, E11.5, and E12.5 and analyzed embryos 
at E13.5 (Figure 8, A–D), or administered tamoxifen at E10.5 and 
E11.5, analyzing embryos at E14.5 (Figure 8, E–L). Using both 
regimes, Gata2ΔLEC embryos exhibited pronounced edema (Fig-
ure 8, C and I, arrows) and enlarged jugular lymph sacs. The phe-
notype of blood-filled jugular lymph sacs and dermal lymphatic 
vessels was, however, most prominent with the E10.5, E11.5, and 
E12.5 tamoxifen regime. Due to the extremely edematous nature 
of the embryos, it was not possible to obtain sections of suffi-
ciently intact morphology for the analysis of LVV development, 
though it is presumable that the blood-filled lymphatic phenotype 
would likely occur as a result of defective LVV development. In the 
Gata2ΔLEC embryos that were administered tamoxifen at E10.5 and 
E11.5 and analyzed at E14.5, though edema was obvious, blood-
with Gata2fl/fl mice (55) (GataΔEC). Given our finding that GATA2 
binds to the PROX1 –11 kb element and regulates PROX1 expres-
sion, we investigated whether Gata2 is required for the initiation 
of Prox1 expression in lymphatic endothelial progenitor cells in 
the cardinal veins. As Prox1 expression is initiated in the cardi-
nal veins at approximately E9.75, Tie2-Cre–mediated deletion 
should provide an ideal model with which to target Gata2 prior 
to the stage at which Prox1 is first turned on. Analysis of GataΔEC 
embryos at E11.5 revealed no striking vascular defects compared 
with control embryos (Figure 7, A and E). Moreover, PROX1 was 
apparent in lymphatic endothelial progenitor cells in the cardi-
nal veins (Figure 7, F–H), and the exit of progenitor cells from the 
veins to form the initial lymphatic vascular plexus was not obvi-
ously perturbed (Figure 7, F–H) compared with control counter-
parts (Figure 7, B–D).
In accordance with previous studies, deletion of Gata2 in vas-
cular and hematopoietic compartments resulted in embryonic 
demise around E14. E13.5 GataΔEC embryos were edematous; had 
dramatically enlarged, blood-filled lymph sacs; and exhibited 
multiple areas of hemorrhage (Figure 7, N, Q, and R, asterisks, 
Figure 6. OSS induced elevation of FOXC2 is dependent on GATA2. hLECs were trans-
fected with control or GATA2 siRNA and cultured under static (A, D, G, and J) conditions, 
or subjected to laminar shear stress (LSS; B, E, H, and K) or OSS (C, F, I, and L) for 48 
hours (4 dyn/cm2, 1/4 Hz). Immunostaining revealed reduced nuclear FOXC2 levels in 
GATA2 siRNA–treated hLECs in response to OSS (L compared with I). Scale bars: 50 μm.
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at E16.5 revealed that GataΔLEC embryos exhibited edema, blood-
filled dermal lymphatic vessels, and pooling of blood in the jugular 
region: phenotypes not observed in control littermates (Figure 9, 
A and F). Whole-mount immunostaining of embryonic skin illus-
trated that the dermal lymphatic vessels were bulbous, irregular 
in shape, and blood filled (Figure 9, B–E and G–J). In addition, 
ectopic association of vascular smooth muscle cells (SMCs) with 
dermal lymphatic vessels was observed in GataΔLEC embryos 
(Figure 9H, arrows), a phenotype reminiscent of that observed 
in Foxc2–/– mice (15). Accordingly, FOXC2 levels appeared much 
lower in the lymphatic vessels of GataΔLEC embryos compared 
with their control counterparts (Supplemental Figure 8). Analysis 
of our GATA2 ChIP-Seq data revealed a prominent GATA2 bind-
filled lymphatics were not apparent, and accordingly, no striking 
abnormalities in LVV development were observed (Figure 8, E–L). 
In the majority of cases, GATA2 remained detectable in at least 
a few cells in the LVV region in of E14.5 embryos that had been 
administered tamoxifen at E10.5 and E11.5 (Figure 8K). Taken 
together, these data suggest that administration of tamoxifen at 
E12.5 could be a crucial determinant of Gata2 excision efficiency 
in the LVV compartment.
To investigate the consequences of Gata2 deletion on lym-
phatic vessel valve development, which is initiated in the dermal 
lymphatic vasculature at approximately E16.5, tamoxifen was 
administered to pregnant females at E12.5, E13.5, and E14.5, and 
embryos were analyzed at E16.5 and at E18.5. Analysis of embryos 
Figure 7. Lymphatic vessel hyperplasia in Gata2ΔEC embryos. E11.5 Gata2ΔEC embryos appear phenotypically normal (A and E). Whole-mount immunos-
taining for PROX1 (red) and LYVE-1 or NRP2 (cyan) demonstrated that PROX1-positive lymphatic endothelial progenitor cells are specified and migrate 
away from the cardinal veins of Gata2ΔEC embryos (F and G). Immunostaining of transverse sections for α smooth muscle actin (αSMA; red), PROX1 (green), 
and CD31 (cyan) confirmed PROX1 expression in lymphatic endothelial progenitor cells of the cardinal veins of Gata2ΔEC embryos (D and H; arrowheads) and 
migration of these cells from the veins (D and H, arrows). Boxed regions in A–E correspond to areas shown in B, C, F, and G. E13.5 Gata2ΔEC embryos exhibit 
severe edema, pooling of blood in the jugular region (N, arrowhead), and focal dermal hemorrhages (R, asterisks), compared with control littermates 
(Cre-negative;Gata2fl/fl; I and M). LVVs appeared multi-layered (O) with reduced PROX1 levels in the venous leaflets (Podoplanin-negative, Endomucin- 
low) of Gata2ΔEC embryos (P, arrows) compared with controls (J and K). PROX1 levels in lymphatic leaflets (Podoplanin-positive, Endomucin-negative) 
of Gata2ΔEC embryos were not substantially altered (O and P). Jugular lymph sacs (Q) and dermal lymphatic vessels (R, arrowheads) were enlarged and 
blood-filled in Gata2ΔEC embryos, phenotypes not observed in control embryos (L and M). Magnified images of boxed regions in J and O are shown in K and 
P, respectively. Gray scale bars: 5 mm. White scale bars: 50 μm (K and P) or 100 μm (all panels excluding K and P). CV, cardinal vein; DA, dorsal aorta; JV, 
jugular vein; Lin+, APC mouse lineage antibody cocktail used to detect hematopoietic cells.
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GataΔLEC mesenteries. Likewise, lymphatic vessels appeared bul-
bous, and valve development appeared to be perturbed in the 
skin of E18.5 GataΔLEC embryos (Supplemental Figure 10). Taken 
together, our data illustrate that Gata2 is essential for lymphatic 
vessel valve development to be initiated.
To assess the consequences of Gata2 deletion on later stages of 
valve maturation, we next administered tamoxifen to pups at P4. 
Assessment of valve morphology and PROX1 levels in the valves of 
mesenteric collecting vessels at P8 revealed substantially reduced 
PROX1 levels in the valves of GataΔLEC pups (Figure 10, C, D, E, F, 
H, I, K, and L) compared with controls (Cre-negative;Gata2fl/fl, Fig-
ure 10, A, B, G, and J). In addition, cells within the valve territories 
appeared more disorganized (Figure 10, C, E, H, and I). Investiga-
tion of β-galactosidase levels in the mesenteric lymphatic vessel 
valves of P8 Prox1-CreERT2 Gata2fl/+ ROSA26R mice administered a 
single dose of tamoxifen at P4 confirmed efficient Cre activity in 
lymphatic vessel valves (Supplemental Figure 11, A–P). Moreover, 
PROX1 levels were reduced in the valves of Prox1-CreERT2 Gata2fl/+ 
ROSA26R mice (Supplemental Figure 11, G and O) and the cells in 
which β-galactosidase levels were highest correlated with the most 
obvious reduction in PROX1 levels (Supplemental Figure 11, F–H, 
and N–P). To investigate later-stage consequences of Gata2 dele-
tion on the mesenteric lymphatic vasculature, pups administered 
tamoxifen at P4 were analyzed at P10. The phenotypes of dysmor-
ing peak 17 kb downstream of the FOXC2 gene in hLECs (Sup-
plemental Figure 9A), and the ability of GATA2 to drive reporter 
gene expression from this element was confirmed in luciferase 
assays (Supplemental Figure 9B). Together with our previous data 
demonstrating that Gata2 knockdown results in decreased Foxc2 
levels in primary embryonic mLECs (3), these data suggest that 
GATA2 regulates Foxc2 expression in the lymphatic vasculature 
and that the +17 kb element is potentially an important site for 
GATA2-mediated control of Foxc2.
The number of clusters of PROX1- and FOXC2-high cells at 
lymphatic vessel branchpoints in the skin, indicative of initial 
valve–forming territories, also appeared reduced in GataΔLEC 
embryos at E16.5 (Figure 9, D and I, arrowheads), suggesting 
that the initiation of valve development might be affected as 
a result of Gata2 deletion. To investigate a potential defect in 
valve development more closely, we assessed lymphatic vessel 
development in the mesentery of GataΔLEC embryos and their 
control littermate counterparts (Cre-negative;Gata2fl/fl) at E18.5. 
Striking defects in lymphatic vessel structure were observed 
in GataΔLEC embryos at this stage of development; lymphatic 
vessels appeared bulbous and were poorly organized (Figure 
9, K–V). Moreover, in contrast to control littermates in which 
tightly organized valve-forming territories were obvious (Figure 
9, L, P, and S–V), no sign of valve development was apparent in 
Figure 8. Lymphatic vascular phenotypes in 
E13.5 and E14.5 Gata2ΔLEC embryos. Prox1- 
CreERT2 Gata2fl/+ male mice were crossed with 
Gata2fl/fl female mice, and tamoxifen was 
administered at E10.5, E11.5, and E12.5, fol-
lowed by analysis at E13.5 (A–D), or E10.5 and 
11.5, followed by analysis at E14.5 (E–L). E13.5 
Gata2ΔLEC embryos exhibit striking edema (C, 
arrow) and greatly enlarged, blood-filled jugu-
lar lymph sacs (arrowhead, C and D), compared 
with control littermates (Cre-negative;  
Gata2fl/fl, A and B). At E14.5, Gata2ΔLEC embryos 
exhibit edema (I, arrow). Immunostaining of 
coronal E14.5 tissue sections demonstrated 
no obvious morphological abnormalities in 
LVVs of Gata2ΔLEC mice (J–L) compared with 
control littermates (F–H). Scale bars: 5 mm (A, 
C, E, and I) or 100 μm (B, D, F–H, and J–L). JLS, 
jugular lymph sac; JV, jugular vein.
Downloaded from http://www.jci.org on April 4, 2018.   https://doi.org/10.1172/JCI78888
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
2 9 8 9jci.org   Volume 125   Number 8   August 2015
ducts of GataΔEC/+ mice 1 hour following injection (Figure 12, A 
and B), though in 2 of 9 GataΔEC/+ mice, Evans Blue was barely 
detectable. In 2 cases, blood was observed in the thoracic ducts 
of adult GataΔEC/+ mice (Figure 12C). Quantification of thoracic 
duct areas in a cohort of mice revealed that the thoracic ducts of 
adult GataΔEC/+ mice were significantly larger in calibre than their 
control counterparts (Figure 12, A–D). Taken together, these data 
illustrate alterations in lymphatic vessel structure and deficiencies 
in lymphatic vascular transport function in adult GataΔEC/+ mice.
Discussion
Here, we identify a crucial role for Gata2 in lymphatic vascu-
lar development and, in particular, demonstrate that Gata2 is 
required for the formation and maintenance of lymphovenous 
and lymphatic vessel valves. Gata2-deficient lymphatic vessels 
appear bulbous, are aberrantly invested with vascular SMCs and 
phic valves and bulbous lymphatic vessels were substantially more 
severe at this stage, suggesting a progressive decline in valve orga-
nization following Gata2 deletion (Figure 11). Like at P8, PROX1 
levels were decreased in some valve territories of GataΔLEC pups at 
P10, though intriguingly in other cases, PROX1 levels remained 
high in valves and were elevated in the lymphangion regions of 
mesenteric vessels. In all cases, the cells within valve territories 
were markedly disorganized (Figure 11, J–L, and N–P). We hypoth-
esize that the elevation of PROX1 levels observed at P10 is a sec-
ondary effect of disrupted flow and vessel distension that occurs 
as a consequence of the loss of valve function.
To investigate the capacity of the lymphatic vasculature to 
efficiently transport lymph in the setting of Gata2 deficiency, 
we injected adult GataΔEC/+ mice with Evans Blue dye and moni-
tored the transport of dye from the footpads to the thoracic duct. 
In the majority of cases, Evans Blue was visible in the thoracic 
Figure 9. Lymphatic vessel valve development is perturbed in Gata2ΔLEC embryos. Prox1-CreERT2 Gata2fl/+ male mice were crossed with Gata2fl/fl female mice, 
and tamoxifen was administered at E12.5, E13.5, and E14.5. E16.5 Gata2ΔLEC embryos exhibit blood-filled dermal lymphatic vessels and pooling of blood in 
the jugular region (F), phenotypes not observed in control littermates (Cre-negative;Gata2fl/fl, A). Whole-mount immunostaining of skin from E16.5 Gata2ΔLEC 
embryos revealed enlarged, blood-filled dermal lymphatic vessels (G–J) that were ectopically associated with vascular SMCs (H, arrows), phenotypes not 
observed in control littermates (B–E). Reduced numbers of PROX1-high valve territories (I, arrowheads) were obvious in E16.5 Gata2ΔLEC embryos compared 
with littermate controls (D, arrowheads). Gata2ΔLEC embryos appeared indistinguishable from control littermates at E18.5 (K and O). Whole-mount immu-
nostaining of E18.5 mesenteries demonstrated bulbous mesenteric lymphatic vessels in Gata2ΔLEC embryos (P–R), lacking organized valve forming territories 
(L–N). Single-channel images of boxed regions in L and P are shown in S and T, and U and V, respectively. Scale bars: 5 mm (A, F, K, and O) or 100 μm (B–E, 
G–J, L–N, and P–R). Lin+; APC mouse lineage antibody cocktail used to detect hematopoietic cells.
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ing analyses revealed very low levels of GATA2 protein 
throughout the majority of the embryonic vasculature. 
Notably higher protein levels were obvious in arterial 
endothelial cells and, most prominently, in the cells that 
comprise lymphovenous and lymphatic vessel valves. One 
explanation for the divergence between Gata2 mRNA and 
protein levels could be differential posttranscriptional/
posttranslational regulation in distinct vascular beds; 
indeed, our earlier work documenting that miR-451 levels 
are elevated in primary embryonic BECs compared with 
LECs (3) provides one potential mechanism by which this 
could be accomplished. An important role for GATA2 
in arteries may underlie the hemorrhagic phenotype of 
Gata2ΔEC mice described by us and others, as well as the 
association of GATA2 SNPs in patients with early-onset 
coronary artery disease (9–11). Targeted mutation of 
gata2a in zebrafish has recently been demonstrated to 
result in defective morphogenesis of the dorsal aorta, 
resulting in arterial-venous shunts and suggesting that 
arterial defects could also contribute to the vascular phe-
notype observed in Gata2ΔEC mice. To date, however, we 
have not observed any striking abnormalities in dorsal 
aorta morphology (12).
Conditional deletion of Gata2 throughout the vascu-
lar and hematopoietic compartments using either +9.5 kb 
enhancer-driven (13) or VE-cadherin Cre lines (43) has 
been reported to result in both hematopoietic and vas-
cular defects, including anaemia, hemorrhage, edema, 
and blood-filled lymphatic vessels. Targeted deletion of 
the Gata2 +9.5 kb regulatory element, essentially ablat-
ing Gata2 in the endothelial and hematopoietic lineages, 
results in similar phenotypes (14). Our documentation of 
aberrant LVV formation in Gata2ΔEC mice likely explains the phe-
notypes of edema and blood-filled lymphatic vessels observed 
in the mutant mice reported in earlier studies, though we can’t 
at present discount a potential contribution from hematopoietic 
cell defects to this phenotype. On the basis of published work, the 
lineage most likely to contribute to blood-filled lymphatics is the 
megakaryocyte/platelet lineage, recently documented to func-
tion together with the LVV to prevent the entry of blood cells to 
the lymphatic vasculature (35), and a lineage in which Gata2 has 
documented roles (45, 58).
Intriguingly, blood-filled lymph sacs and lymphatic vessels 
were prominent in E13.5 GataΔLEC embryos in which Gata2 exci-
sion was induced by the administration of tamoxifen at E10.5, 
E11.5, and E12.5, but were not obvious in E14.5 GataΔLEC embryos 
in which Gata2 excision was induced at E10.5 and E11.5. Accord-
ingly, no prominent defects in LVV formation were observed in 
these E14.5 GataΔLEC mice. Though disruption to tissue morphol-
ogy in E13.5 GataΔLEC embryos has restricted rigorous analysis of 
LVV morphology, we expect that either the structure or function 
of this valve is impaired, resulting in the blood-filled lymphatic 
phenotype. The presence of edema in Gata2ΔLEC embryos at both 
E13.5 and E14.5, even in the absence of blood-filled jugular lymph 
sacs, is suggestive of lymphatic vessel dysfunction and a potential 
role for Gata2 in the lymphatic vasculature prior to the initiation of 
lymphatic vessel valve development. Our analyses of Gata2 exci-
exhibit dysmorphic lymphatic vessel valves (Figure 13). Under-
pinning this phenotype, we identify putative enhancer elements 
bound by GATA2 at both PROX1 and FOXC2 loci and reveal that 
neither of these transcription factors is elevated in prospective 
valve-forming territories in the absence of Gata2. Intriguingly, our 
data suggest that GATA2 binding at the PROX1 –11 kb locus is not 
required for the initiation of PROX1 expression in lymphatic endo-
thelial progenitor cells in the cardinal veins but may be important 
as a rheostat to “dial up” PROX1 levels in valve-forming endothe-
lial cells. We furthermore demonstrate that GATA2 is mechano- 
responsive and is elevated in hLECs in response to OSS, providing 
a mechanism by which GATA2 levels may be increased to initiate 
the process of valve development. Our data provide new insight 
to the mechanisms by which only a select catalogue of GATA2 
mutations result in primary lymphedema by revealing that mis-
sense mutations from Emberger patients, but not those found in 
hematological disorders in the absence of lymphedema, result in 
near complete loss of GATA2 function with respect to their ability 
to regulate the expression of genes important for lymphatic vessel 
valve development, including Prox1.
Though enigmatic to date, work from multiple studies has 
implicated GATA2 in vascular development. An enhancer ele-
ment located in the fourth intron of Gata2, also known as the +9.5 
element (57), has been reported to drive reporter gene expression 
uniformly through the vasculature (5), though our immunostain-
Figure 10. Gata2 is required for lymphatic vessel valve maintenance. Gata2ΔLEC and 
littermate control (Cre-negative;Gata2fl/fl) pups were injected with tamoxifen at P4. 
Whole-mount immunostaining of mesenteries at P8 with PROX1 (cyan) and CD31 
(green) demonstrated reduced PROX1 levels in lymphatic vessel valves of Gata2ΔLEC 
mice (C, E, H, and I), compared with littermate controls (A and G). Blood vascular 
patterning was indistinguishable from littermate controls. Scale bars: 100 μm (A–F) 
or 50 μm (G–L).
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marker of repressed, inactive chromatin (60) — was not detected 
at PROX1 –11 kb in hLECs but was prominent in both hBECs and 
K562 cells. Taken together, these data suggest that GATA2 may 
be poised at the PROX1 –11 kb enhancer in BECs and that yet-
to-be-identified chromatin remodeling/transcription factors are 
important for switching this enhancer to the “on” state in LECs. 
An important answer to the question of how PROX1 transcription 
is temporally and spatially controlled will come from defining the 
relative contribution of the –11 kb element compared with other 
potential enhancer elements.
How is it that GATA2 levels are distinctly higher in valve-
forming territories? Our data suggest that at least one mechanism 
responsible for the elevation of GATA2 levels in lymphatic vessel 
and LVV valves is mechanical in nature and mediated by OSS, 
though additional stimuli are likely involved in regulating GATA2 
levels within the lymphatic vasculature and between distinct vas-
cular endothelial compartments. Established regulators of GATA2 
transcription include GATA2 itself, as well as GATA1, reported to 
repress GATA2 expression in hematopoietic cells (37). GATA2 is 
both positively and negatively regulated by the Notch signalling 
pathway; NOTCH1/RBJκ is required to initiate Gata2 expres-
sion in hematopoietic stem cells in the embryonic aorta-gonad- 
mesonephros region (61), while the Notch-induced gene Hes1 
subsequently negatively regulates Gata2 in hematopoietic stem 
cells of the AGM, controlling the production of functional HSC 
(62). NOTCH1 function has recently been shown to be impor-
tant for lymphatic vessel valve development; loss of NOTCH1 
results in fewer valves, disrupted reorientation of valve endothe-
lial cells, and reduced levels of valve markers, including ITGα9 
and FN-EIIIA (25). Whether or not Notch signalling is important 
sion in the LVV region of E13.5 and E14.5 GataΔLEC embryos sug-
gests that tamoxifen administration at E12.5 might be critical for 
efficient Gata2 deletion in the LVV using the Prox1-CreERT2 line. In 
support of this possibility, our analysis of β-galactosidase levels in 
the LVV region of E14.5 Prox1-CreERT2 ROSA26R embryos follow-
ing one tamoxifen administration at E12.5 revealed that the major-
ity of cells in the LVV region were labeled.
While a number of recent studies have contributed to our 
understanding of how PROX1 transcription is controlled, there 
remains a dearth of knowledge in this arena. Our data identify 
GATA2 as an important transcriptional regulator of PROX1 and 
reveal a novel enhancer element 11 kb upstream of the first, non-
coding exon of PROX1 that is bound by GATA2, FOXC2, and 
NFATC1. Given our data demonstrating that Prox1 expression 
is still initiated in lymphatic endothelial progenitor cells in the 
cardinal veins in the absence of Gata2, we hypothesize that the 
binding of Gata2 to the –11 kb enhancer element is not required to 
“switch on” Prox1, but rather is important for “dialling up” Prox1 
levels in valve-forming cells. There seems little doubt that tran-
scriptional cofactors, in addition to GATA2, are required to coor-
dinate PROX1 transcription differentially in LECs and BECs, since 
we detected binding of GATA2 at the PROX1 –11 kb locus in both 
cell types, though at a greater magnitude in hLECs. In support of 
this hypothesis, ChIP studies identified differences in the chro-
matin architecture of the PROX1 –11 kb locus in hLECs compared 
with hBECs. Monomethylation of H3K4Me1, a mark indicative 
of active or poised enhancer elements (59), was associated with 
the PROX1 –11 kb locus in hLECs and, to a lesser extent, in hBEC; 
however, it was not present in K562 cells, an erythroid cell line 
negative for PROX1. In contrast, trimethylation of H3K27Me3 — a 
Figure 11. Gata2 deletion results in 
degeneration of lymphatic vessel 
valves and lymphatic vessel disten-
sion. Gata2ΔLEC and littermate control 
(Cre-negative; Gata2fl/fl) pups were 
injected with tamoxifen at P4. Whole-
mount immunostaining of mesen-
teries at P10 with PROX1 (cyan) and 
CD31 (green) demonstrated severely 
dysmorphic lymphatic vessel valves 
and distended lymphatic vessels in 
Gata2ΔLEC mesenteries (C–H, J–L, and 
N–P), compared with littermate con-
trols (A, B, I, and M). Scale bars:  
100 μm (A–H) or 50 μm (I–P).
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cular endothelial cells remains to be established and is an avenue 
of research we are actively pursuing. At the posttranslational level, 
GATA2 is reportedly subject to control by phosphorylation, acetyla-
tion, and sumoylation (37), though whether any of these modifica-
tions has an impact on the high levels of nuclear GATA2 present in 
valve-forming territories remains to be determined.
Our assessment of the impact of germline GATA2 mutations 
found in Emberger syndrome on protein structure, compared 
with those found only in hematological disorders (germline or 
somatic), has provided insight to the reasons why some but not all 
germline GATA2 mutations result in lymphedema. Analysis of the 
structure of the GATA2 zinc fingers containing Emberger muta-
tions R361L, C373R, and R396Q, together with their binding to 
the GATA site in the PROX1 –11 kb enhancer element, revealed 
that these mutations exhibit a near complete ablation of DNA 
binding due to alteration in key DNA-binding residues or severe 
disruption to protein folding. In contrast, GATA2 mutants associ-
ated with hematological disorders but not lymphedema retained 
some capacity to bind the PROX1 –11 kb enhancer. This finding is 
in agreement with hypotheses proposed by us (3) and others (49), 
suggesting that effectively null haploinsufficiency of GATA2 is 
the critical factor predisposing to lymphedema onset. We don’t 
rule out the possibility, however, that additional insults such as 
infection, defective immune cell trafficking resulting in inflam-
mation, and/or injury may contribute to lymphedema onset in 
patients. It remains enigmatic that mutations such as 355del, 
essentially loss of function in all assays tested, are not to date 
associated with lymphedema. Additional phenotypes reported 
in patients carrying GATA2 mutations/deletions that may reflect 
a role for GATA2 as a general regulator of valve development 
and function include venous thromboses and culture-negative 
for the control of Gata2 levels in valve endothelial cells remains 
to be assessed. Other signalling axes that regulate Gata2 expres-
sion include BMP signalling, required to induce Gata2 and specify 
ventral identity in Xenopus (63), and retinoic acid (RA) signalling, 
shown to impact on the transcriptional activity of GATA2 by virtue 
of a direct interaction between the zinc fingers of GATA2 and the 
DNA-binding domain of RA receptor α (RARα) (64). Of interest, 
BMP9 has recently been shown to control lymphatic vessel valve 
formation (31), and our own recent work revealed aberrant devel-
opment of LVVs in Cyp26b1–/– mice in which RA signalling is ele-
vated (65). Potential regulation of GATA2 by both of these path-
ways will be the subject of future investigation.
Recent large-scale ChIP-Seq studies analyzing the binding of 
multiple transcription factors across distinct hematopoietic cell 
types have revealed key insights to the identity of transcription-
factor complexes and target genes important for programming 
cell identity (44, 45). Such studies in hematopoietic cell lineages 
have revealed that GATA2 works cooperatively with transcription 
factors, including RUNX1, SCL/TAL1, FLI1, LYL1, LMO2, and 
ERG (44, 45). The identity of GATA2 transcriptional cofactors in 
endothelial cells and, in particular, in lymphatic versus blood vas-
Figure 12. Lymphatic vascular defects in adult Gata2ΔEC mice. Adult 
heterozygous Gata2ΔEC/+ mice injected with Evans Blue dye exhibited col-
lecting lymphatic vessels of substantially larger caliber (B–D) than con-
trols (A). Thoracic duct area was measured using ImageJ in control (n = 5) 
and heterozygous Gata2ΔEC/+ (n = 6) adult mice (D). *P < 0.05, by 2-tailed 
Student’s t-test. Reduced transport of Evans Blue dye to the thoracic 
duct and blood within the thoracic duct (C; arrow) were also observed in 
Gata2ΔEC/+ mice. Scale bars: 1 mm. TD, thoracic duct.
Figure 13. Model depicting mechanisms by which Gata2 regulates lym-
phatic vascular development. GATA2 is elevated in valve-forming territories 
at the onset of lymphatic vessel valve development and regulates the levels 
of PROX1 and FOXC2 in valve-forming endothelial cells. Deletion of Gata2 
in the lymphatic vasculature prior to the initiation of lymphatic vessel valve 
development results in reduced FOXC2 levels throughout the lymphatic 
vasculature, ectopic recruitment of vascular SMCs to dermal lymphatic ves-
sels, dilated lymphatic vessels, and arrested valve development. Postnatal 
deletion of Gata2 in the lymphatic vasculature following valve assembly 
results in diminished levels of PROX1 in the endothelial cells comprising 
lymphatic vessel valves and consequent valve disorganization.
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ChIP-Seq data accession. ChIP-Seq data has been deposited in the 
European Nucleotide Archive (ENA), accession number PRJEB9436 
(http://www.ebi.ac.uk/ena/data/view/PRJEB9436).
Statistics. Analysis of luciferase activity of all GATA2 mutants 
compared with WT (shown in Figure 1E and Supplemental Figure 1B) 
was performed using 1-way ANOVA with Dunnett’s multiple-compar-
isons test. For all other statistical analyses, P values were calculated 
using the 2-tailed Student’s t test. P values of less than 0.05 were con-
sidered statistically significant.
Study approval. Experiments using mice were approved and con-
ducted in accordance with the SA Pathology/CALHN Animal Ethics 
Committee and Australian National Health and Medical Research 
Council (NHMRC) guidelines.
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endocarditis (49). Since many of the genes and cellular events 
important for lymphatic vessel valve development are also impor-
tant for venous valve development (32), it stands to reason that 
venous valve development and/or function may also be affected 
in patients with GATA2 mutations, a scenario that may contribute 
to venous thromboses. Likewise, our demonstration that Gata2 is 
also present in cardiac valves suggests that GATA2 mutations may 
potentially result in defective cardiac valve development, one of 
the factors underlying culture-negative endocarditis. An impor-
tant role for a second GATA family member, Gata4, has been doc-
umented during atrioventricular valve development in mice (66) 
and mutations in GATA4 have been associated with human atrial 
and ventricular septal defects and pulmonary valve stenosis (67).
In conclusion, our study defines a crucial role for Gata2 in lym-
phatic vascular development and reveals that Gata2 is essential for 
the morphogenesis of lymphovenous and lymphatic vessel valves. 
We provide new insight to the mechanisms by which selected 
GATA2 mutations result in lymphedema in human patients, 
demonstrating that complete loss of transcriptional activity with 
respect to the control of genes important for lymphatic vessel valve 
development underlies this phenotype. Our work has identified a 
potentially “valve selective” enhancer element 11 kb upstream of 
the PROX1 locus that is bound by GATA2, FOXC2, and NFATC1 
in endothelial cells and that is, in general, “on” in lymphatic endo-
thelial cells and “poised” in blood vascular endothelial cells, at the 
epigenetic level. Our work sets the stage for future investigations 
to define the precise mechanisms, in terms of the transcriptional 
cofactors and target genes of GATA2, that are important for the 
process of valve development and has the potential to uncover 
new targets to which the design of novel agents able to promote 
valve development and/or function could be designed.
Methods
For a full description of Methods, see Supplemental Methods online.
Mice. Prox1-CreERT2 (56) Gata2fl/fl (55), Tie2-Cre (54), and ROSA26R 
Cre reporter (68) mice have been previously described.
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